Alcon Research

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

260

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Completed

Evaluation of the Impact of Residual Astigmatism on the Visual Performance With Clareon Vivity

Jul 11, 2026

Recruiting

Contralateral Claims Study of Clareon Vivity Pro

Earlier

Sep 2, 2025TrialReformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

Jan 15, 2025TrialA Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Oct 15, 2024TrialA Study Designed to Evaluate Tear Production

Oct 8, 2024TrialA Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

Oct 7, 2024TrialAn Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations

Sep 4, 2024TrialNext Generation Rocklatan

3 more events

Aug 21, 2024TrialA Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness

Dec 6, 2023TrialStudy of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Feb 25, 2022FDAAcuvue Theravision With Ketotifen — ACUVUE THERAVISION WITH KETOTIFEN

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Acuvue Theravision With KetotifenMar 27, 2028 Acuvue Theravision With KetotifenJun 27, 2030

Regulatory

Regulatory Timeline

20062 events

FDADec 1

Acuvue Theravision With Ketotifen — ALAWAY

Application NDA021996 (NDA)

FDAOct 19

Acuvue Theravision With Ketotifen — ZADITOR

Application NDA021066 (NDA)

20221 event

FDAFeb 25

Acuvue Theravision With Ketotifen — ACUVUE THERAVISION WITH KETOTIFEN

Application NDA022388 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)